[HTML][HTML] IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis
G Szabo, M Mitchell, CJ McClain, S Dasarathy… - Hepatology, 2022 - journals.lww.com
Conclusions Metabolomic signatures identify three NAFLD subgroups, independent of
histological disease severity. These signatures align with known CVD and genetic risk
factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation
in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.
histological disease severity. These signatures align with known CVD and genetic risk
factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation
in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.